Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

(2010) Meletios Dimopoulos et al.   CANCER

The potential of immunomodulatory drugs in the treatment of solid tumors

(2010) Angus Dalgleish et al.   Future Oncology

Distribution of Lenalidomide Into Semen of Healthy Men After Multiple Oral Doses

(2010) Nianhang Chen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia

(2010) Farrukh T. Awan et al.   LEUKEMIA & LYMPHOMA

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

(2009) Thomas M. Habermann et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

(2009) Thomas E. Witzig et al.   JOURNAL OF CLINICAL ONCOLOGY

Mechanism of action of lenalidomide in hematological malignancies

(2009) Venumadhav Kotla et al.   Journal of Hematology & Oncology

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

(2009) H Quach et al.   LEUKEMIA

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

(2008) M. Wang et al.   BLOOD

Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction

(2008) Gondi Kumar et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY